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Abstract
Background: Adaptive designs are a wide class of methods focused on improving the power, efficiency and
participant benefit of clinical trials. They do this through allowing information gathered during the trial to be
used to make changes in a statistically robust manner – the changes could include which treatment arms
patients are enrolled to (e.g. dropping non-promising treatment arms), the allocation ratios, the target sample
size or the enrolment criteria of the trial. Generally, we are enthusiastic about adaptive designs and advocate
their use in many clinical situations. However, they are not always advantageous. In some situations, they
provide little efficiency advantage or are even detrimental to the quality of information provided by the trial.
In our experience, factors that reduce the efficiency of adaptive designs are routinely downplayed or ignored
in methodological papers, which may lead researchers into believing they are more beneficial than they
actually are.
Main text: In this paper, we discuss situations where adaptive designs may not be as useful, including
situations when the outcomes take a long time to observe, when dropping arms early may cause issues and
when increased practical complexity eliminates theoretical efficiency gains.
Conclusion: Adaptive designs often provide notable efficiency benefits. However, it is important for
investigators to be aware that they do not always provide an advantage. There should always be careful
consideration of the potential benefits and disadvantages of an adaptive design.
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Background
There is a great desire to improve the efficiency of clin-
ical trials, which are expensive, time-consuming and
contribute to the high cost of drug development [1].
One initiative to address this is the use of adaptive de-
signs, which provide the opportunity to use data accrued
during the trial to make relevant changes [2, 3]. Potential
changes relate to the allocation of patients to specific
treatment arms, enrolment criteria and the target sample
size. Generally, the scope of potential changes is clearly
laid out prior to trial commencement.
Adaptive designs can lead to improved efficiency (ei-
ther fewer participants on average to achieve the same
level of statistical power to detect a true treatment effect,
or higher power for the same number of participants)
and trial attractiveness to enrolled participants (e.g. by
closing ineffective arms earlier and allocating more
participants to treatments that have shown more prom-
ise from data accrued so far). Some argue that adaptive
trials are more ethical, although this is a complex and
controversial statement. We refer the reader to work on
this subject (e.g. [4, 5]) and restrict our attention to the
narrower context of what number and proportion of
participants receive ineffective treatments.
Adaptive designs have been used in a range of settings,
including a small trial testing new imaging techniques
[6], a two-arm trial investigating cannabis use in
multiple sclerosis [7] and ongoing large oncology trials
testing a pipeline of treatments [8, 9]. A range of adapta-
tions are possible, as shown in Fig. 1 and elaborated on
by Pallmann et al. [2]. Several reviews have been pub-
lished investigating properties of published adaptive
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designs, including study characteristics [10, 11], and
views from stakeholders on their utility [12].
As researchers with an interest in methodology of adap-
tive designs, we are often approached to collaborate to
apply them in practice. It has been hugely pleasing to us
to see increasing enthusiasm amongst clinical investiga-
tors for their use. This is often for good reasons, with the
benefits of adaptive designs being compelling. However, in
some situations, the drawbacks of using an adaptive ap-
proach outweigh the benefits. Although reasons for this
have been mentioned in disparate papers, primarily statis-
tical, we believe this issue is not sufficiently emphasised in
the literature that promotes adaptive trials. Here, we pro-
vide some guidance on situations where we believe the
trial design should be kept more straightforward.
Long-term outcomes
For adaptive designs to improve the efficiency of a trial,
the information at an interim analysis must be useful for
predicting what would occur if the trial were to continue
to the end. As an example, consider a multi-arm, multi-
stage (MAMS) trial that allows several experimental
treatments to be tested against a shared control, and for
experimental treatment arms to be dropped from the
trial early if one or more treatments are not showing
promising evidence of benefit. This is potentially advan-
tageous to future participants in the trial who are less
likely to be allocated to an ineffective treatment and also
allows increased efficiency. Both of these advantages are
strongly dependent on making a reliable decision at the
interim analysis and to avoid wrongly dropping an actu-
ally effective treatment. In order to do this, the decision
needs to be made on outcome information from a rea-
sonable number of participants. This requires that the
outcome being used to decide whether to drop one or
more treatment arms should be observed sufficiently
quickly (compared to the planned recruitment length of
the trial). If it is not, the trial may be complete before a
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Fig. 1 Assessment of the impact of potential adaptive design limitations on different types of adaptive trial features. aAssuming no pause in
recruitment; bPrimary endpoint with an intermediate observation period. Some adaptive designs were extracted from Table 1 from Pallmann
et al. [2] (with the removal of dose-finding designs); MAMS have several arms and could include any of the above adaptive features at the interim
stages with added complexity
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sufficient number of outcomes have been observed to
make any material difference to the trial. If an inter-
mediate outcome is being used, this must (1) be highly
predictive of the primary outcome, accepting that the as-
sociation between the intermediate outcome and the
substantive outcome may be altered by the intervention
[13], and (2) it must also be observed quickly enough to
allow modification of the trial design. If neither of these
is the case, then one of two possibilities will occur,
namely (1) at the interim analysis, there will be many
participants who have been recruited but are not yet in a
position to contribute information at the interim ana-
lysis; or (2) recruitment will be paused at the interim
analysis until all recruited participants have been
assessed. Neither of these possibilities is desirable. The
first will mean that participants who are recruited but
not yet assessed cannot contribute to, or benefit from,
the interim analysis; the second will mean that the trial
will take much longer, considering even that it is feasible
to pause recruitment (it usually is not).
Methodological papers often do not consider the rate of
enrolment versus the length of follow-up for outcomes
when quantifying the efficiency advantages of adaptive
designs. Often, participant outcomes are assumed to be
available immediately after recruitment – clearly unrealis-
tic in many situations – with the implication that the
reported benefits of these designs in the literature are
overinflated. The various adaptive study designs are likely
to be differentially affected by this delay (Fig. 1). Two-arm
sample size re-assessment designs, which allow the
planned sample size to be increased after an interim
analysis, are less affected, whereas MAMS or outcome-
adaptive randomisation designs (more participants are
randomised to better performing arms) are more af-
fected [14, 15].
We consider two examples to illustrate this point. The
first is Immunotace, an ongoing randomised phase II
trial in Birmingham Cancer Research UK Clinical Trials
Unit assessing the benefit of the addition of dendritic
cells in an immunotherapy trial in hepatocellular carcin-
oma (ISRCTN: 11889464). Originally, this trial had been
planned with an adaptive design. The primary outcome
of progression-free survival rate at 12 months was to be
used to allow the potential for stopping at the interim
analysis for futility after 23 participants per arm. With
the projected recruitment rate (two participants/month)
the trial would have reached its full sample size of 70
patients by the time the first stage participants reached
12months follow-up of progression-free survival. The
timeline of the trial if participants were recruited as
planned (Fig. 2a, two participants per month) and at a
slower rate (Fig. 2b, one participant per month) clearly
shows that, in the first case, the pre-planned adaptation
would have been pointless, with no possibility to stop
participants being exposed to a potentially ineffective
therapy. Instead, this trial was re-designed using a sim-
pler, single-stage design and efficiency was gained by
changing the primary outcome to a time-to-event out-
come. The adaptation would have provided more utility
if either the recruitment rate had been slower (e.g. one
patient per month; Fig. 2b) or there had been an inform-
ative intermediate endpoint observed more quickly.
The second example is the TAILoR trial [16], which is
a four-arm, two-stage trial testing three doses of telmi-
sartan for the reduction of insulin resistance in HIV-
positive individuals. The arms are treated as distinct (as
opposed to applying a dose–response model) as there
was reason to believe that the relationship between dose
and outcome would be complex. The outcome was
change in Homeostatic Model Assessment – Insulin Re-
sistance from baseline to 24 weeks. The total planned
recruitment length, according to the ISRCTN registra-
tion (ISRTCTN51069819), was 28months. The design
used the methodology of Magirr et al. [17] to control the
total chance of making any type I error at 5%. The target
sample size was set to be 336 patients with a 24-week
outcome, which corresponds to 42 patients recruited to
each of the four treatment arms (control, 20 mg, 40 mg,
80 mg) at each of the two stages. At the end of the first
stage, a t test statistic for each of the active doses versus
control was calculated. If any test statistic was above
2.782, the trial would be stopped for efficacy and that
dose recommended for a phase III trial; if any test statis-
tic was below 0, it would be dropped for futility. If no
experimental arm stopped for efficacy and at least one
did not stop for futility, then the second stage would
recruit 42 additional patients per remaining arm. Final
test statistics, using data from both stages, would be
compared to a critical value of 2.086.
Having delay does hurt the efficiency gain – whilst the
required number of first-stage patients were reaching 24
weeks follow-up, second-stage patients were being re-
cruited. We explored the effect of the length of the
endpoint delay in simulations. We consider the endpoint
delay varying from 1 to 48 weeks and simulated 10,000
trial replicates for each. This allowed us to explore the ef-
fect of delay on the statistical properties. We considered
two scenarios, namely when all doses had the same effect
as control (null scenario) and when two doses had no ef-
fect and one dose had a standardized effect of 0.545 (alter-
native scenario). Figure 3 shows the expected sample size
of the trial under each scenario and the proportion of
participants allocated to the effective treatment in the
alternative scenario. Clearly, the delay had a substan-
tial effect on the expected sample size and the advan-
tages to patients. Nevertheless, with the actual 24-
week delay observed in the trial, there was a substan-
tial benefit from the adaptive approach, wherein the
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sample size needed (on average) was reduced and
there was an increase in the proportion of patients al-
located to the best treatment.
It should be noted that the time taken to perform the
interim analysis (see later section on logistical complexity)
was not included in the 24-week delay, and thus, in prac-
tice, the delay might have been longer. We consider in a
later section logistical issues that may either prolong the
interim analysis, require substantially more trial resources,
or lower the quality of the information on the endpoint
Fig. 2 Timeline of the first example trial (ISRCTN 11889464) if participants were recruited at a rate of two per month (a) and one per month (b).
Stage 1 enrolment represents the pre-planned number of individuals who would provide information at the interim analysis. The red part of the
x axis denotes stage 2 participants who are recruited prior to the interim analysis being started; the green part denotes stage 2 participants who
are recruited after the interim analysis starts (and who thus may benefit from the adaptive design)
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assessed at the interim. Any of these issues will reduce the
benefits given by the adaptive design.
Limitations due to early stopping
Many adaptive designs allow early stopping of the trial
or of individual treatment arms, within a MAMS study.
This stopping could be for futility, when there is little
prospect of a positive finding given the data seen up to
that point, or for efficacy when there is already sufficient
evidence to conclude the treatment is efficacious.
Generally, as argued above, this early stopping is ad-
vantageous. It means that fewer participants are re-
quired, on average, the trial can finish quicker, and fewer
participants may be allocated to ineffective treatment
arms. However, it can also cause a number of problems
that may outweigh the advantages. Stopping early for ef-
ficacy means that the trial may not provide convincing
information on secondary outcomes, safety or subgroup
effects. Additionally, there is often scepticism that early
stopping might reflect a random high and the treatment
effectiveness might not be as great as suggested [18].
Moreover, if the precision of the estimated treatment ef-
fects is broad due a reduced sample size, this may be less
convincing in terms of changing clinical practice (or Na-
tional Institute of Health and Care Excellence guidance).
Stopping early for futility may also mean that advantages
provided by the treatment in a participant subgroup or
on an important secondary outcome may be missed;
thus, it is important to consider whether stopping early
runs the risk of missing out on important information. It
is also important to consider what happens to partici-
pants allocated to an arm that is stopped early. Should
they stop treatment or switch to another arm? For ac-
curate reporting of the dropped arm, they would still be
followed, but this may be contrary to arguments in
favour of the adaptive approach that appeal to improved
patient benefit of trial participants.
Limitations due to additional administrative and
logistical complexity
Another issue that, in our experience, is frequently
underestimated by investigators is the additional com-
plexity that an adaptive design causes to the conduct of
a trial. To provide an advantage over a non-adaptive
design, interim analyses must be conducted quickly and
to a high standard. This involves having an effective in-
frastructure within the trial team that may require con-
siderable investment of resources. For example, return
of data for the analysis has to be prompt and complete,
and data queries and cleaning have to be to a high
standard throughout the trial so that the data snapshot
for the interim analysis does not exclude large amounts
of pending or incomplete data. In addition, effective
communication within the trials team, as well as be-
tween trial investigators and the data monitoring com-
mittee, is required to understand the impact of the
adaptive features.
Any delays in conducting interim analyses or imple-
menting adaptations will reduce the efficiency advan-
tage of an adaptive approach in exactly the same way
as using an outcome that takes longer to observe
(Fig. 1). To our knowledge, there is no paper system-
atically investigating how quickly and to what level of
quality interim analyses have been performed in adap-
tive designs.
An example of a trial which has made available infor-
mation on the time taken is the STAMPEDE trial, a
MAMS trial allowing early stopping for lack-of-benefit.
Fig. 3 Properties of the TAILoR trial assuming different delay lengths in the endpoint. The actual endpoint was assessed 24 weeks after randomisation.
Plotted trial properties were simulated using 10,000 simulation replicates for each potential endpoint delay length between 1 and 48weeks.
a Expected sample size averaged over 10,000 simulation replicates for each delay length. Blue dashed line represents the properties of the trial under
the null scenario, when all experimental doses have the same efficacy as control; red solid line represents the properties under the alternative scenario,
when one dose has a standardised effect of 0.545 and the others have the same efficacy as control. b Proportion of patients who were allocated to
the effective dose in the alternative scenario (as in a, one dose had a standardised effect of 0.545 and the others 0)
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In Sydes et al. [19], details are presented about an in-
terim analysis where recruitment to an arm was termi-
nated due to lack of benefit. The time lapse from the
database being frozen to the decision to drop the arm
being ratified was just over 2 months. This process is im-
pressively quick given that it involves an analysis being
conducted as well as meetings of the data monitoring
committee and trial steering committee. The decision of
the trial steering committee was implemented in sites on
the same day. It is likely that the typical length of time
taken in adaptive designs is considerably longer.
An additional example of overcoming logistical diffi-
culties is the BATTLE-2 trial, testing four treatments for
lung cancer using a Bayesian adaptive randomisation de-
sign. In section 4 of Gu et al. [20], the substantial infra-
structure for ensuring high-quality information is
described.It would be interesting to contrast the above
requirements for adaptive designs to the needs for data
monitoring in non-adaptive designs. It is our opinion
that adaptive trials likely require more resources, but
this needs further research.
Weighing the pros and cons of adaptive designs
Adaptive designs undoubtedly have benefits for improv-
ing the efficiency of testing experimental treatments in
many situations. However, in other situations, the bene-
fits may be marginal and not sufficient to justify the
drawbacks. We believe that it is vital to properly assess
the benefits of an adaptive design prior to embarking on
one and that no single method (i.e. adaptive or non-
adaptive) should be the default for a particular clinical
setting. It is important that theoretical work that pro-
poses and promotes adaptive designs clearly lays out any
reduction in their reported efficiency benefits when
there is substantial delay in outcome evaluation. It is
also important to carefully consider reducing the com-
plexity of an adaptive design when the efficiency gains
are marginal. For example, in our experience, it is rare
that having more than two interim analyses during a
trial provides enough additional benefit to justify the
additional burden unless the trial is over a very long
period of time or involves adding in new arms as the
trial progresses.
Having an efficient infrastructure that reliably delivers
the promised increase efficiency of adaptive designs will
likely increase the financial costs of the trial. This is an
area where more research is needed to assess the add-
itional cost of an adaptive design and when is it worth-
while. Once there is more information on costs, and
better information on the efficiency provided by adaptive
trials in real-world scenarios, investigators and funders
should carefully consider which design is most appropri-
ate for the specific setting of the trial. Careful consider-
ation of outcomes, recruitment, data quality and trial
complexity should be built into developing the trial de-
sign and assessing its properties. Further methodological
research is needed to provide specific guidelines about
when being adaptive is worthwhile.
Conclusions
We do not aim to suggest that adaptive designs should
not be used. In fact, they are frequently the best option
for efficiency reasons and from the perspective of trial
participants. However, we also wish to ensure it is well
understood by investigators that they are not a universal
panacea that should be used in all trials. Investigators
should carefully consider the potential benefits and
drawbacks of the design used as well as whether it is ac-
tually feasible to perform with the resources available.
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